Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476916 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| SCHEMBL5476914 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5475451 | 0.99 | SLC6A4 (0.44) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5475448 | 0.99 | SLC6A4 (0.44) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5475455 | 0.99 | SLC6A4 (0.44) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| SCHEMBL5481778 | 0.86 | SLC6A4 (0.54) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| SCHEMBL5481779 | 0.86 | SLC6A4 (0.54) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| SCHEMBL5481780 | 0.86 | SLC6A4 (0.54) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5478091 | 0.85 | SLC6A4 (0.55) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5478089 | 0.85 | SLC6A4 (0.55) | SLC6A2SLC6A3SLC6A4NOS2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072859-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY (US) | 2007-03-29 | — | — | US | claimed |
| EP-1725518-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005092835-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072859-A1 | Pharmaceutical compounds | ADRB3, HTR3C, SLC6A2 | SLC6A2 3/4885SLC6A3 13/4885SLC6A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.